Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the...

Full description

Bibliographic Details
Main Authors: Daniel Baumann, Tanja Hägele, Julian Mochayedi, Jennifer Drebant, Caroline Vent, Sven Blobner, Julia Han Noll, Irena Nickel, Corinna Schumacher, Sophie Luise Boos, Aline Sophie Daniel, Susann Wendler, Michael Volkmar, Oliver Strobel, Rienk Offringa
Format: Article
Language:English
Published: Nature Publishing Group 2020-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-020-15979-2
id doaj-82d30f0ec62647d88279190f5c3cf28a
record_format Article
spelling doaj-82d30f0ec62647d88279190f5c3cf28a2021-05-11T08:17:57ZengNature Publishing GroupNature Communications2041-17232020-05-0111111810.1038/s41467-020-15979-2Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapyDaniel Baumann0Tanja Hägele1Julian Mochayedi2Jennifer Drebant3Caroline Vent4Sven Blobner5Julia Han Noll6Irena Nickel7Corinna Schumacher8Sophie Luise Boos9Aline Sophie Daniel10Susann Wendler11Michael Volkmar12Oliver Strobel13Rienk Offringa14Department of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergDepartment of Surgery, Heidelberg University HospitalDepartment of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center HeidelbergImmune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the tumor microenvironment.https://doi.org/10.1038/s41467-020-15979-2
collection DOAJ
language English
format Article
sources DOAJ
author Daniel Baumann
Tanja Hägele
Julian Mochayedi
Jennifer Drebant
Caroline Vent
Sven Blobner
Julia Han Noll
Irena Nickel
Corinna Schumacher
Sophie Luise Boos
Aline Sophie Daniel
Susann Wendler
Michael Volkmar
Oliver Strobel
Rienk Offringa
spellingShingle Daniel Baumann
Tanja Hägele
Julian Mochayedi
Jennifer Drebant
Caroline Vent
Sven Blobner
Julia Han Noll
Irena Nickel
Corinna Schumacher
Sophie Luise Boos
Aline Sophie Daniel
Susann Wendler
Michael Volkmar
Oliver Strobel
Rienk Offringa
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
Nature Communications
author_facet Daniel Baumann
Tanja Hägele
Julian Mochayedi
Jennifer Drebant
Caroline Vent
Sven Blobner
Julia Han Noll
Irena Nickel
Corinna Schumacher
Sophie Luise Boos
Aline Sophie Daniel
Susann Wendler
Michael Volkmar
Oliver Strobel
Rienk Offringa
author_sort Daniel Baumann
title Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_short Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_full Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_fullStr Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_full_unstemmed Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_sort proimmunogenic impact of mek inhibition synergizes with agonist anti-cd40 immunostimulatory antibodies in tumor therapy
publisher Nature Publishing Group
series Nature Communications
issn 2041-1723
publishDate 2020-05-01
description Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the tumor microenvironment.
url https://doi.org/10.1038/s41467-020-15979-2
work_keys_str_mv AT danielbaumann proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT tanjahagele proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT julianmochayedi proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT jenniferdrebant proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT carolinevent proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT svenblobner proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT juliahannoll proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT irenanickel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT corinnaschumacher proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT sophieluiseboos proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT alinesophiedaniel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT susannwendler proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT michaelvolkmar proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT oliverstrobel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
AT rienkoffringa proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
_version_ 1721450915679961088

Similar Items